In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia

Current thalassemia gene therapy protocols require the collection of hematopoietic stem/progenitor cells (HSPCs), in vitro culture, lentivirus vector transduction, and retransplantation into myeloablated patients. Because of cost and technical complexity, it is unlikely that such protocols will be a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Invest
Päätekijät: Wang, Hongjie, Georgakopoulou, Aphrodite, Psatha, Nikoletta, Li, Chang, Capsali, Chrysi, Samal, Himanshu Bhusan, Anagnostopoulos, Achilles, Ehrhardt, Anja, Izsvák, Zsuzsanna, Papayannopoulou, Thalia, Yannaki, Evangelia, Lieber, André
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2018
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355219/
https://ncbi.nlm.nih.gov/pubmed/30422819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI122836
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia